^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Focus V (anlotinib)

    i
    Other names: AL3818, AL-3818, ALTN, AL 3818
    Company:
    Advenchen, Sino Biopharm
    Drug class:
    Multi-tyrosine kinase inhibitor
    Related drugs:
    3d
    A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults (clinicaltrials.gov)
    P2, N=49, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Focus V (anlotinib) • capecitabine • Duoenda (mitoxantrone liposomal)
    3d
    Long-term survival with eribulin in an elderly patient with inoperable retroperitoneal well-differentiated liposarcoma: a case report and literature review. (PubMed, Front Oncol)
    Due to age, comorbidities, and unresectable disease, first-line therapy with anlotinib was initiated. This case suggests that eribulin may provide durable disease control and is a well-tolerated therapeutic option for elderly patients with inoperable retroperitoneal WDLPS, providing preliminary evidence for its potential to achieve long-term tumor stability and maintain quality of life in this vulnerable population. Multidisciplinary assessment and individualized treatment strategies remain essential in optimizing outcomes.
    Journal
    |
    MDM2 (E3 ubiquitin protein ligase)
    |
    Focus V (anlotinib) • Halaven (eribulin mesylate)
    3d
    Penpulimab and Gemcitabine With or Without Anlotinib in Metastatic Nasopharyngeal Carcinoma: A Randomized, Open-Label, Multicenter Phase 2 Study. (PubMed, Int J Cancer)
    This prospective exploratory phase 2 study employed a three-cohort, two-phase design to evaluate the potential of anlotinib as a substitute for cisplatin in gemcitabine-penpulimab combinations for metastatic nasopharyngeal carcinoma (NPC) patients who were previously treated with cisplatin-based chemoradiotherapy. The GAP regimen demonstrated a favorable safety and efficacy profile, compared to the GP-PA and GP-P regimens in patients with metastatic NPC. These findings suggest that substituting cisplatin with anlotinib may offer a viable therapeutic strategy for this patient population.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • gemcitabine • Focus V (anlotinib) • Anniko (penpulimab-kcqx)
    9d
    A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC (clinicaltrials.gov)
    P2, N=48, Not yet recruiting, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Focus V (anlotinib) • Fu Mai Ning (luvometinib)
    12d
    Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=40, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=134 --> 40 | Trial completion date: Apr 2027 --> Apr 2026 | Recruiting --> Terminated | Trial primary completion date: Oct 2026 --> Apr 2026; This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    cisplatin • carboplatin • Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr) • etoposide IV • Andewei (benmelstobart) • bemarituzumab (AMG 552)
    13d
    Inhibitory effect of the multi-target TKI, anlotinib, in 5-FU resistant colorectal cancer HCT-8/15 cells: down regulation of drug resistance-associated protein expression. (PubMed, Front Oncol)
    Treatment usually includes 5-fluorouracil (5-FU), oxaliplatin, and irinotecan, with 5-FU usually being the first choice. Anlotinib suppressed the proliferation of 5-FU-resistant colon cancer cells by preventing entry into S phase, thus sensitizing cells to 5-FU. Moreover, anlotinib may reverse the effect of 5-FU on drug-resistant cells by down-regulating the expression of multidrug-resistant proteins, in which the AKT signaling pathway may play an important role.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1)
    |
    5-fluorouracil • Focus V (anlotinib) • oxaliplatin • irinotecan
    17d
    Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma (clinicaltrials.gov)
    P2, N=33, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2)
    |
    Focus V (anlotinib) • Andewei (benmelstobart)
    17d
    Doxorubicin plus anlotinib for the adjuvant treatment of stage I–II high-grade uterine sarcoma: a single-arm exploratory study (ChiCTR2600121235)
    P=N/A, N=43, Obstetrics and Gynecology Hospital Affiliated to Fudan University; Obstetrics and Gynecology Hospital Affiliated to Fudan University
    New trial
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    Focus V (anlotinib) • doxorubicin hydrochloride
    17d
    Sacituzumab Tirumotecan in Combination with Anlotinib in Previously Treated Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Prospective, Single-Arm, Phase II Study (ChiCTR2600120856)
    P2, N=33, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P2 trial
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    Focus V (anlotinib) • Jiataile (sacituzumab tirumotecan)
    17d
    A Multicenter, Open-Label, Randomized, Phase II Clinical Trial of Trastuzumab Rezetecan-based Therapy for Brain Metastases in HER2-Positive Breast Cancer (ChiCTR2600120221)
    P2, N=108, ChongQing university cancer hospital; ChongQing university cancer hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • Focus V (anlotinib) • capecitabine • Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811)
    17d
    A Single-Arm, Multicenter, Phase II Clinical Study Protocol of Sintilimab Combined with Anlotinib and TP Regimen Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (ChiCTR2600119085)
    P2, N=25, Recruiting, Mianyang Central Hospital; Mianyang Central Hospital
    New P2 trial
    |
    Focus V (anlotinib) • Tyvyt (sintilimab)
    18d
    A Multicenter, Dual-Cohort Exploratory Clinical Study of Anlotinib Plus Bemelstobart as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma (ChiCTR2600118343)
    P=N/A, N=66, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
    New trial
    |
    docetaxel • Focus V (anlotinib) • albumin-bound paclitaxel • irinotecan